Procyon Advisors LLC Acquires 8,907 Shares of Bristol Myers Squibb Company $BMY

Procyon Advisors LLC grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 33.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,801 shares of the biopharmaceutical company’s stock after acquiring an additional 8,907 shares during the period. Procyon Advisors LLC’s holdings in Bristol Myers Squibb were worth $1,615,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Bristol Myers Squibb by 1.8% during the second quarter. Vanguard Group Inc. now owns 194,925,206 shares of the biopharmaceutical company’s stock valued at $9,023,088,000 after buying an additional 3,522,202 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after acquiring an additional 10,195,775 shares during the last quarter. Geode Capital Management LLC grew its stake in Bristol Myers Squibb by 1.6% during the second quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after acquiring an additional 723,459 shares in the last quarter. Norges Bank bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at $1,554,154,000. Finally, Ameriprise Financial Inc. lifted its stake in Bristol Myers Squibb by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after purchasing an additional 432,158 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $56.60 on Friday. The firm has a market capitalization of $115.22 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 9.44 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The business has a 50 day simple moving average of $51.74 and a 200-day simple moving average of $48.06. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.Bristol Myers Squibb’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be issued a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wells Fargo & Company raised their price objective on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $52.00 to $61.00 in a research note on Monday, December 15th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 price objective (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Morgan Stanley reiterated an “underweight” rating and set a $37.00 target price (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Finally, Guggenheim reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. Seven equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $56.86.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.